医学会议频道
MedSci梅斯医学APP下载
&&SCAND J RHEUMATOL 期刊介绍
MedSci 2016年期刊智能查询系统(2015年度)
期刊关键词：
支持模糊智能搜索，多关键词组合
期刊领域：
请选择大类
综合性期刊
请选择二级分类
填数字，填写自己想选择的杂志影响因子范围，可留空
排列方式：
按年文章量从多到少
按年文章量从少到多
按影响因子从大到小
按影响因子从小到大
IF上升速度从大到小
IF上升速度从小到大
文章数量往往与发表的周期有关
以下是对&SCAND J RHEUMATOL &杂志介绍
缩写名/全名
SCAND J RHEUMATOL /scandinavian journal of rheumatology |
(电子版ISSN)
被收录情况
Science Citation Index Science Citation Index Expanded Current Contents - Clinical Medicine Current Contents - Life Sciences BIOSIS Previews
CiteScore分区
所属分类：Rheumatology分区Q2[23/54]所属分类：Immunology and Allergy分区Q3[82/162]所属分类：Immunology分区Q3[109/184]
IF变化趋势
CiteScore指数
2 (2015年度)
出版社或管理机构杂志由 & &出版或管理。 & &ISSN号：
杂志简介/稿件收录要求The journal is an international scientific journal covering clinical and experimental aspects of rheumatic diseases. Scandinavian Journal of Rheumatology is essential reading for rheumatologists and also for general practitioners, orthopaedic surgeons, radiologists, pharmacologists, pathologists and health professionals with an interest in patients with rheumatic diseases. Scandinavian Journal of Rheumatology is published for the Scandinavian Rheumatology Research Foundation and is the official journal of the Scandinavian Society for Rheumatology. Scandinavian Journal of Rheumatology publishes original papers within the various fields of clinical and experimental rheumatology, such as: clinical aspects of rheumatic disorders including pharmacotherapy, prophylaxis, surgical
laboratory investigations, including mainly biochemistry, immunology, immunopathology, microbiology, histopathology, pathophysiol radiological, magnetic, and ot and epidemiologicial, genetic, and social aspects. Editorials, short papers and review articles are also published. Brief letters to the Editor will be accepted. Reviews of new books are included. The scientific standard is the only criterion for accepting an article for publication. "Scandinavian" does not imply a journal restricted to Scandinavian research. The journal welcomes international papers and invites both Scandinavian and other investigators to submit their manuscripts for publication in the journal. All papers are published in English.
杂志主页/投稿链接 &(点击4099次)(点击1次)
[IF: 1.702]
[IF: 2.946]
[IF: 3.236]
[IF: 2.042]
[IF: 3.979]
[IF: 2.495]
[IF: 2.118]
[IF: 2.307]
[IF: 1.843]
[IF: 1.245]
ClinicalTrials
关注Medsci
声明：MedSci(梅斯医学)登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。文章内容仅供专业医生参考，具体诊断和治疗请咨询专科医生。
MedSci备案号
扫码领取IF曲线
IF连续增长的期刊
即刻扫码下载梅斯医学App，免费订阅“命中率/一审周期历史变化曲线”。梅斯海量服务数据，即将发布！医学会议频道
MedSci梅斯医学APP下载
&&JCR-J CLIN RHEUMATOL期刊介绍
MedSci 2016年期刊智能查询系统(2015年度)
期刊关键词：
支持模糊智能搜索，多关键词组合
期刊领域：
请选择大类
综合性期刊
请选择二级分类
填数字，填写自己想选择的杂志影响因子范围，可留空
排列方式：
按年文章量从多到少
按年文章量从少到多
按影响因子从大到小
按影响因子从小到大
IF上升速度从大到小
IF上升速度从小到大
文章数量往往与发表的周期有关
以下是对&JCR-J CLIN RHEUMATOL&杂志介绍
缩写名/全名
JCR-J CLIN RHEUMATOL/jcr-journal of clinical rheumatology |
(电子版ISSN)
被收录情况
Science Citation Index Expanded Current Contents - Clinical Medicine
CiteScore分区
所属分类：Rheumatology分区Q3[30/54]
IF变化趋势
CiteScore指数
1.09 (2015年度)
出版社或管理机构杂志由 & &出版或管理。 & &ISSN号：
杂志简介/稿件收录要求The Journal of Clinical Rheumatology® Practical Reports on Rheumatic & Musculoskeletal Diseases is the peer-reviewed, bimonthly journal that rheumatologists asked for! Each issue contains practical information on patient care in a clinically oriented, easy-to-read format. Our commitment is to timely, relevant coverage of the topics and issues shaping current practice. We pack each issue with original articles, case reports, reviews, brief reports, expert commentary, letters to the editor, and more. This is where you'll find the answers to tough patient management issues as well as the latest information about technological advances affecting your practice.
杂志主页/投稿链接 &(点击3585次)(点击1次)
[IF: 1.702]
[IF: 2.946]
[IF: 2.042]
[IF: 2.495]
[IF: 2.118]
[IF: 2.307]
[IF: 1.843]
[IF: 1.245]
[IF: .269]
[IF: .569]
ClinicalTrials
关注Medsci
声明：MedSci(梅斯医学)登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。文章内容仅供专业医生参考，具体诊断和治疗请咨询专科医生。
MedSci备案号
扫码领取IF曲线
IF连续增长的期刊
即刻扫码下载梅斯医学App，免费订阅“命中率/一审周期历史变化曲线”。梅斯海量服务数据，即将发布！Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report
| SpringerLink
This service is more advanced with JavaScript available, learn more at http://activatejavascript.org
Tell us about your experience on SpringerLink and you could win a MacBook Pro.
Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case reportJianyong WuYan SongHeng LiJianghua ChenReview ArticleDOI:
10.-009-0723-7Cite this article as: Wu, J., Song, Y., Li, H. et al. Eur J Clin Pharmacol (69. doi:10.-009-0723-7
Fibrates are used to manage mixed dyslipidemia. However, these drugs have the potential risk of inducing rhabdomyolysis. This paper gives an overview of the literature on rhabdomyolysis associated with fibrate therapy.We reported a case of rhabdomyolysis induced by fenofibrate and reviewed the published rhabdomyolysis cases associated with fibrate therapy.Seventy-six published rhabdomyolysis cases associated with fibrates were evaluated, and a nondiabetic, nonhypertensive patient who presented with rhabdomyolysis caused by fenofibrate was reported. The onset time of the reaction varied between 36 h and 6 months. Gemfibrozil was the most frequent agent associated with rhabdomyolysis, followed by bezafibrate, fenofibrate, ciprofibrate, and clofibrate. Twenty-three cases were associated with fibrate monotherapy and 54 with fibrate therapy combined with statins or other drugs potentially interacting with fibrates. Sixteen cases had chronic renal failure before fibrate therapy, and 6 had hypothyroidism. Fifty-four complicated acute renal failure. After discontinuation of the fibrates and hydration, most patients recovered.Chronic renal failure may be a risk factor for rhabdomyolysis associated with fibrates. Although rhabdomyolysis usually occurred when fibrates were combined with statins, a well-known class of agents that potentially induce rhabdomyolysis, precautions against serious adverse effects should also be taken with fibrate monotherapy.Drug adverse reactionRhabdomyolysisFibratesDrug interaction (142 kb)Supplementary Table 1Characteristics of rhabdomyolysis cases associated with fibrates (PDF 141 kb)1.Knopp RH (1999) Drug treatment of lipid disorders. N Engl J Med 341(7):498–5112.Davidson MH, Armani A, McKenney JM, Jacobson TA (2007) Safety considerations with fibrate therapy. Am J Cardiol 99(6A):3C–18C3.Baer AN, Wortmann RL (2007) Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 19(1):67–734.Vanholder R, Sever MS, Erek E, Lameire N (2000) Rhabdomyolysis. J Am Soc Nephrol 11(8):5.Tahmaz M, Kumbasar B, Ergen K, Ure U, Karatemiz G, Kazancioglu R (2007) Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. Ren Fail 29(7):927–9306.Yildiz A, Gucuk E, Cay S (2008) A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy. Acta Cardiol 63(4):515–5177.Unal A, Torun E, Sipahioglu MH, Tokgoz B, Kaya MG, Oymak O et al (2008) Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Intern Med 47(11):8.Satarasinghe RL, Ramesh R, Riyaaz AA, Gunarathne PA, de Silva AP (2007) Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis-patient report and literature review. Drug Metabol Drug Interact 22(4):279–2839.Dedhia V, Munsi SC (2007) Myopathy caused by a combination rosuvastatin and fenofibrate. J Assoc Physicians India 55:152–15310.Akoglu H, Yilmaz R, Kirkpantur A, Arici M, Altun B, Turgan C (2007) Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure. Ann Pharmacother 41(1):143–14711.Yang KC, Fang CC, Su TC, Lee YT (2005) Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD. Am J Kidney Dis 45(3):e57–6012.Morimoto S, Fujioka Y, Tsutsumi C, Masai M, Okumura T, Yuba M et al (2005) Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment. Am J Med Sci 329(4):211–21313.Kursat S, Alici T, Colak HB (2005) A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. Clin Nephrol 64(5):391–39314.Jacob SS, Jacob S, Williams C, Deeg MA (2005) Simvastatin, fenofibrate, and rhabdomyolysis. Diabetes Care 28(5):125815.Ireland JH, Eggert CH, Arendt CJ, Williams AW (2005) Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 142(11):949–95016.Fontaine C, Guiard-Schmid JB, Slama L, Essid A, Lukiana T, Rondeau E et al (2005) Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 19(16):17.Layne RD, Sehbai AS, Stark LJ (2004) Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother 38(2):232–23418.Yen TH, Chang CT, Wu MS, Huang CC (2003) Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglyceridemia while receiving continuous veno-venous hemofiltration therapy. Ren Fail 25(1):139–14319.Barker BJ, Goodenough RR, Falko JM (2003) Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 26(8):20.Arenas J, Fernandez-Moreno MA, Molina JA, Fernandez V, del Hoyo P, Campos Y et al (2003) Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil. Neurology 60(1):124–12621.Su M, Hoffman RS, Flomenbaum M (2002) Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis. Am J Forensic Med Pathol 23(3):305–30622.Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A (2002) Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 36(5):820–82323.Marsa Carretero M, Alos Manrique C, Valles Callol JA (2002) Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. Br J Gen Pract 52(476):235–23624.Kind AH, Zakowski LJ, McBride PE (2002) Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. WMJ 101(7):53–5625.Huynh T, Cordato D, Yang F, Choy T, Johnstone K, Bagnall F et al (2002) HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J 32(9–10):486–49026.Bairaktari E, Seferiadis K, Liamis G, Psihogios N, Tsolas O, Elisaf M (2002) Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine. Clin Chem 48(7):27.Atmaca H, Sayarlioglu H, Kulah E, Demircan N, Akpolat T (2002) Rhabdomyolysis associated with gemfibrozil-colchicine therapy. Ann Pharmacother 36(11):28.Mastroianni CM, d'Ettorre G, Forcina G, Lichtner M, Corpolongo A, Coletta S et al (2001) Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS 15(6):820–82129.Lau TK, Leachman DR, Lufschanowski R (2001) Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case. Texas Heart Inst J 28(2):142–14530.Kamaliah MD, Sanjay LD (2001) Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore Med J 42(8):368–37231.Hendriks F, Kooman JP, van der Sande FM (2001) Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil. Nephrol Dial Transplant 16(12):32.Federman DG, Hussain F, Walters AB (2001) Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 94(10):33.Bruno-Joyce J, Dugas JM, MacCausland OE (2001) Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann Pharmacother 35(9):34.Sharobeem KM, Madden BP, Millner R, Rolfe LM, Seymour CA, Parker J (2000) Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group. J Cardiovasc Pharmacol Ther 5(1):33–3935.Plotkin E, Bernheim J, Ben-Chetrit S, Mor A, Korzets Z (2000) Influenza vaccine—a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate. Nephrol Dial Transplant 15(5):740–74136.Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S (2000) A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy-a case report. Angiology 51(8):695–69737.Oldemeyer JB, Lund RJ, Koch M, Meares AJ, Dunlay R (2000) Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology 94(2):127–12838.Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD (2000) Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm 57(5):461–46439.Alexandridis G, Pappas GA, Elisaf MS (2000) Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 109(3):261–26240.Weissgarten J, Zaidenstein R, Fishman S, Dishi V, Michovitz-Koren M, Averbukh Z et al (1999) Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs? Perit Dial Int 19(2):180–18241.Pogson GW, Kindred LH, Carper BG (1999) Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 83(7):114642.Landesman KA, Stozek M, Freeman NJ (1999) Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med 63(8):455–45743.Clouatre Y, Leblanc M, Ouimet D, Pichette V (1999) Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant 14(4):44.Terrovitou CT, Milionis HJ, Elisaf MS (1998) Acute rhabdomyolysis after bezafibrate re-exposure. Nephron 78(3):336–33745.Duell PB, Connor WE, Illingworth DR (1998) Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 81(3):368–36946.Tal A, Rajeshawari M, Isley W (1997) Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 90(5):546–54747.Ramachandran S, Giles PD, Hartland A (1997) Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. BMJ 314(48.van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ (1996) Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 240(6):403–40449.Panuccio V, Enia G, Parlongo S, Cutrupi S, Zoccali C (1996) Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient. Nephron 73(4):73650.Gorriz JL, Sancho A, Lopez-Martin JM, Alcoy E, Catalan C, Pallardo LM (1996) Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron 74(2):437–43851.Gorriz JL, Sancho A, Alcoy E, Garcia-Ramos JL, Pallardo LM (1995) Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol Dial Transplant 10(12):52.de Alava E, Sola JJ, Lozano MD, Pardo-Mindan FJ (1994) Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants. Nephron 66(2):242–24353.Bedani PL, Perini L, Gilli P (1994) Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis. Nephron 68(4):512–51354.Kanterewicz E, Sanmarti R, Riba J, Trias I, Autonell J, Brugues J (1992) Bezafibrate induced rhabdomyolysis. Ann Rheum Dis 51(4):536–53855.Pierce LR, Wysowski DK, Gross TP (1990) Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264(1):71–7556.Goldman JA, Fishman AB, Lee JE, Johnson RJ (1989) The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 32(3):358–35957.Haubenstock A, Schrocksnadel W, Bauer K, Schmidt P, Gabl F (1984) Predominance of lactate dehydrogenase isoenzyme 1 in a patient with bezafibrate-induced rhabdomyolysis. Clin Chem 30(9):58.Smals AG, Beex LV, Kloppenborg PW (1977) Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy. N Engl J Med 296(16):94259.Waring WS, Wrate J, Bateman DN (2006) Olanzapine overdose is associated with acute muscle toxicity. Hum Exp Toxicol 25(12):735–74060.Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L et al (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21):61.Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E et al (2003) Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163(5):553–56462.Jacobson TA, Zimmerman FH (2006) Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 8(1):35–41 quiz 42–3363.Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365(–142864.Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346(7):539–54065.Franssen R, Vergeer M, Stroes ES, Kastelein JJ (2009) Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 11(2):89–9466.Maiguma T, Fujisaki K, Itoh Y, Makino K, Teshima D, Takahashi-Yanaga F et al (2003) Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn Schmiedebergs Arch Pharmacol 367(3):289–296Jianyong Wu1Yan Song1Heng Li1Jianghua Chen11.Kidney Disease Center, First Affiliated Hospital, College of MedicineZhejiang UniversityHanghzouPeople’s Republic of China
Print ISSN
Online ISSN
Publisher Name
Springer-Verlag
Buy (PDF)EUR&34,95
Unlimited access to full article
Instant download (PDF)
Price includes local sales tax if applicable
Export citation
Share article
We use cookies to improve your experience with our site.您所在位置： &
&nbsp&&nbsp&nbsp&&nbsp
北京首钢公司中轴型脊柱关节炎患病率调查.pdf81页
本文档一共被下载：
次 ,您可免费全文在线阅读后下载本文档
文档加载中...广告还剩秒
需要金币：200 &&
你可能关注的文档：
··········
··········
＼IYllIlllllll／l／lll／lllllll／llllllllllll／lllll／lllll7Y197538
军医进修学院
研究生学位论文原创性声明
秉承我院“敬业、勤奋、求实、创新"的学风，本人声明：所呈交的论
文是我本人在导师指导下进行的研究工作及取得的研究成果。据我所知，除
了文中特别加以标注和致谢的地方外，论文中不包含任何其他个人或集体已
经发表或撰写过的研究成果，也不含为获得我院或其他教育机构的学位及证
书而使用过的材料，对本文的研究做出贡献的个人或集体，均以在文中作了
明确的说明并表示谢意。
申请学位论文与资料若有不实之处，本人承担一切相关责任。
论文作者签名7奎呻鹇
日期：冲f．刁
指导教师签名：
期：缈抄了，y7
军医进修学院
研究生学位论文版权使用授权书
本人保证毕业离院后，发表论文或使用论文工作成果时署名单位为军医
进修学院或解放军总医院。学院有权保留并向国家有关部门或机构送交论文
原件、复印件和电子版本，可以采用影印、缩印、扫描或其他手段保存论文
以供被查阅或借阅。学院可以公布学位论文的全部或部分内容 保密内容除
论文作者签名：
期：洲口．f刁
指导教师签名：
军医进修学院硕士学位论文
缩略词表…．．…
正在加载中，请稍后...The Journal of Immunology
The JI publishes novel, peer-reviewed findings in all areas of experimental immunology, including innate and adaptive immunity,
inflammation, host defense, clinical immunology, autoimmunity and more.
The JI is published by
THANK YOU, REVIEWERS!
The JI thanks the
who reviewed manuscripts in the past year.
Publish-Ahead-of-Print:
February 1, 1916 -
Collected Articles
Sign up for
Article Statistics}